bioAffinity Regains Nasdaq Compliance, Ensures Continued Trading

bioAffinity Technologies, Inc. ( (BIAF) ) has issued an update.

On October 15, 2025, bioAffinity Technologies announced it has regained compliance with Nasdaq’s listing requirements, ensuring its common stock and warrants continue trading on the Nasdaq Capital Market. This compliance allows the company to focus on advancing its CyPath® Lung test and broader diagnostic pipeline, while a mandatory one-year panel monitor will oversee adherence to the equity rule, with potential delisting if compliance is not maintained.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.

The overall stock score is primarily driven by the company’s weak financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further contribute to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage cancer and other lung diseases. Their primary product, CyPath® Lung, is a test for early-stage lung cancer that utilizes advanced flow cytometry and artificial intelligence to detect malignancy. The test is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.

Average Trading Volume: 2,447,051

Technical Sentiment Signal: Sell

Current Market Cap: $11.97M

For an in-depth examination of BIAF stock, go to TipRanks’ Overview page.